Mazières, Julien <br/><br/>
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Mar 2015 
 - 992-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2014.58.3302  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adult<br/>Aged<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Crizotinib<br/>Disease Progression<br/>Disease-Free Survival<br/>Europe<br/>Female<br/>Gene Rearrangement<br/>Humans<br/>Immunohistochemistry<br/>In Situ Hybridization, Fluorescence<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation<br/>Off-Label Use<br/>Prospective Studies<br/>Protein Kinase Inhibitors--therapeutic use<br/>Protein-Tyrosine Kinases--genetics<br/>Proto-Oncogene Proteins--genetics<br/>Pyrazoles--therapeutic use<br/>Pyridines--therapeutic use<br/>Retrospective Studies<br/>Translocation, Genetic<br/>Treatment Outcome